TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06570291: A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.

Sponsor: Wuxi Cellular Biopharmaceutical Group Ltd. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 520 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT06570291 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06570291 Rescue Dossier →